DRUG DISCOVERY

INSIGHTS ON DRUG DISCOVERY

  • Early CMC Work Sets Groundwork For Regulatory Success

    Understand how the more support and guidance small biopharmaceutical companies receive in terms of CMC expertise, the better groundwork it will lay for a successful IND filing.

  • Leverage The Internet Of Things Within The Laboratory

    As science-based organizations look to leverage the internet of things (IoT) within the laboratory, careful consideration must be given to available technologies, data formats, and platforms. 

  • Route Scouting In API Development: A Luxury Or Necessity?

    Until about 30 years ago, “process R&D” in the pharmaceutical market meant just making a chemical process scalable. Most of the brightest chemists chose to spend their time “discovering” molecules rather than studying how to make them on scale, both efficiently and safely. Adequate attention was not paid to critical aspects of scale-up like safety, waste management, or energy efficiency. The pharmaceutical industry even justified their methods by hypothesizing that the benefit of the end product (life-saving medicines) far outweighed the concerns over the amount of waste that was generated. As a result, the pharmaceutical industry became one of the worst-performing sectors in terms of waste produced per unit of product made. Over the years, the pharma industry has recognized the need to change and develop more efficient processes. Thus a new field of chemistry called process research was born.

  • End-to-end Technology Transfer Services In Oral Solids And Sterile

    In the pharmaceutical industry, “technology transfer” refers to the processes that are needed for successful progression of stages ranging from drug discovery, product development, clinical trials to full-scale commercialization or it is the transfer between development and commercialization at different sites within or outside an organization.

  • Ozonolysis Development Solutions For Safety Studies And Scale Up

    Ozonolysis is a widely used reaction in organic synthesis. The reaction was invented by Christian Friedrich Schoenbein in 1840. Alkenes and alkynes are the most common substrates for the ozonolysis reaction. Ozonolysis was an important diagnostic tool for the determination of the position of unsaturation in unknown molecules before the invention and development of spectroscopic techniques for identification and characterization of organic molecules. The reaction was used for structure elucidation work because it provided chemists with smaller and more readily identifiable carbonyl compounds.

More Insights On Drug Discovery

DRUG DISCOVERY MULTIMEDIA

  • The Cost of Failure In Pharma Development: A Risk for Everyone

    Predicting potential problems serves no purpose if it is not accompanied by adequate corrective actions or mitigation strategies to address them. This webinar will also discuss risk mitigation options for both early and late stage development programs.

More Drug Discovery Multimedia

DRUG DISCOVERY SOLUTIONS

  • CDMO For All Phases Of The Drug Life Cycle
    CDMO For All Phases Of The Drug Life Cycle

    Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd with a vast network of development and manufacturing facilities located in North America, Europe and Asia. 

  • CDMO For All Phases Of The Drug Life Cycle Brochure

    Piramal Pharma Solutions is the contract development and manufacturing (CDMO) arm of Piramal Enterprises Ltd with a vast network of development and manufacturing facilities located in North America, Europe and Asia. 

  • High Potency API (HPAPI) Development & Manufacturing
    High Potency API (HPAPI) Development & Manufacturing

    Piramal Pharma Solutions (PPS) is pleased to welcome Ash Stevens LLC as a part of the Piramal Group. Leveraging five decades of Ash Stevens’s operational experience and technical expertise, Piramal’s service offering now includes High Potency API (HPAPI) development and manufacturing capabilities. Located in Riverview, USA, our state-of the-art FDA licensed cGMP facility offers a full range of scale and containment options for high potency API manufacturing.

More From Drug Discovery Solutions

DRUG DISCOVERY & OUTSOURCED PHARMA EVENTS

Certified Copies and ALCOA-C: Essentials Post ICH GCP E6 (R2) Addendum April 23 - 23, 2018
April 23, 2018 | 1:00 - 2:30 PM EDT)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
Instructional Design for GMP Training – Improve Effectiveness and Measurability April 24, 2018
1pm-2:30pm EDT, Online Training)
Price:  $299 - Includes Bonus Handouts!
Measuring CAPA Effectiveness: Critical Tips in Getting the Right CAPA and Showing It Works April 25 - 25, 2018
2pm-3:30pm EDT, Online Training)
Duration:  90-Minutes
Price:  $299 - Includes Bonus Handouts!
The Top Method Validation Mistakes – And How to Avoid Them April 26 - 26, 2018
1pm-2:30pm EST, Online Training)
Duration:  90 Minutes
Price:  $299 - Includes Bonus Handouts!